Cellares, a biotechnology company known as the world’s first Integrated Development and Manufacturing Organization (IDMO), has announced a major new investment. The company revealed that Prime Radiant Fund SLP SICAV-RAIF, a fund advised by Prime Radiant Partners, has invested $50 million as part of its Series D funding round.
With this latest investment, Cellares has now raised a total of $327 million under its Series D financing. This fresh capital gives the company stronger financial support as it moves ahead with its large-scale global expansion plans in cell therapy manufacturing.
The announcement shows growing confidence from investors who believe Cellares has the technology and infrastructure needed to transform the future of advanced medicine production.
Strong Support From Leading Global Investors
Prime Radiant Partners joins a long list of major investors that already support Cellares. Some of the well-known names include ARK Invest, BlackRock-managed investment funds, Eclipse, T. Rowe Price Investment Management, Duquesne Family Office, Baillie Gifford, Intuitive Ventures, EDBI, Gates Frontier, DC Global Ventures, DFJ Growth, and Willett Advisors.
The presence of these investors highlights the strong trust the financial market has placed in Cellares. It also reflects the growing importance of cell therapy manufacturing as demand for advanced medical treatments rises worldwide.
Such strong investor backing gives Cellares the resources it needs to expand faster and strengthen its position in a highly competitive healthcare sector.
Why Prime Radiant Chose Cellares
Walid Gardezi, Co-Founder and Partner at Prime Radiant Partners, explained why the firm decided to invest in Cellares. According to him, cell therapy has already moved beyond scientific research and has become a real commercial opportunity.
However, he pointed out that manufacturing systems needed to support this market at a large scale still do not exist at the level the healthcare industry will require in the future.
He said Cellares has started to build exactly that missing infrastructure. He also noted that Prime Radiant has deep roots in European pharmaceutical services, which gives the firm strong experience in understanding how these markets operate.
Because of this experience, Prime Radiant plans to actively support Cellares as it expands its business across Europe.
Cellares Focuses on Global Expansion
Fabian Gerlinghaus, Co-Founder and Chief Executive Officer of Cellares, also shared his thoughts after the announcement.
He explained that building a global cell therapy manufacturing network requires expansion across all major markets at the same time. According to him, success in this sector depends on creating manufacturing capacity worldwide rather than focusing on one region alone.
Gerlinghaus said Prime Radiant brings valuable operational experience in pharmaceutical services across continental Europe. This makes the firm an important strategic partner for Cellares as the company pushes deeper into European markets.
He also stated that the investors who joined the Series D round show strong belief in both the company’s technology platform and its future growth plans.
New European Factory Under Construction
A large part of this new funding will support the next phase of Cellares’ Smart Factory expansion strategy.
One of the biggest projects currently underway is the company’s new manufacturing facility in Leiden, Netherlands. This European factory is already under construction and will serve drug companies across international markets.
The company said the facility will use the same automated manufacturing infrastructure already available in the United States. This allows drug developers in different regions to receive the same level of production quality and efficiency.
Cellares confirmed that the new facility will become GMP-ready in 2027. GMP, or Good Manufacturing Practice, is a critical standard required in pharmaceutical production to ensure product quality and patient safety.
This factory marks an important step in the company’s plan to create a truly global manufacturing network.
Prime Radiant Brings European Expertise
Prime Radiant Partners brings more than just capital to the partnership.
The investment firm has strong healthcare and pharmaceutical service experience throughout Europe. The company operates from offices in Milan and Munich, two important centers for healthcare business activity in Europe.
Because of this regional experience, Prime Radiant is well positioned to help Cellares expand operations across the continent.
As demand for automated cell therapy production rises in Europe, this partnership may help Cellares move faster and build stronger local relationships with healthcare companies and drug developers.
Growing Demand for Cellares Technology
The latest funding round also reflects growing demand for the company’s manufacturing platform.
Cellares currently supports active programs across several advanced therapy categories. These include CAR T therapies, TCR-T therapies, and progenitor T cell therapies.
The company works with several major drug developers that use its Cell Shuttle platform. These partners include Bristol Myers Squibb, Cabaletta Bio, TScan Therapeutics, and ProTgen.
The Cell Shuttle platform allows automated manufacturing of cell therapies. This automation helps improve speed, consistency, and production scale, which are major challenges in traditional cell therapy manufacturing.
As more healthcare companies enter this market, demand for reliable automated manufacturing solutions continues to rise.
Major Commercial Agreements Strengthen Business
Cellares has already secured major commercial agreements that strengthen its long-term business outlook.
One of the biggest deals is a $380 million global manufacturing agreement with Bristol Myers Squibb. This agreement reserves large-scale commercial manufacturing capacity for Bristol Myers Squibb across facilities in the United States, Europe, and Japan.
This deal shows that major pharmaceutical companies already trust Cellares to support large-scale production of advanced therapies.
The company also signed a separate 10-year commercial supply agreement with Cabaletta Bio in April 2026.
This agreement came after Cellares successfully delivered GMP cell therapy doses to patients through its Cell Shuttle platform for the first time.
This milestone proved that the company’s automated manufacturing system can support real patient treatment under strict pharmaceutical quality standards.
A Big Step Toward the Future of Medicine
The latest Series D funding extension marks another major step forward for Cellares.
With $327 million now raised, support from world-class investors, a new factory under construction in Europe, and major pharmaceutical partnerships already in place, the company is building strong momentum.
Cell therapy continues to become one of the most promising areas in modern medicine. But large-scale production remains one of the biggest challenges in the industry.
Cellares aims to solve that challenge through automation and global manufacturing infrastructure.
As the demand for advanced medical therapies grows worldwide, Cellares now stands in a strong position to become one of the key companies that helps shape the future of healthcare.
Also Read – India Builds Strong Global Startup Partnerships in 2026